Cystine stones
Conditions
Interventions
experimental group:The new "potassium citrate"
Control group:Administer an equivalent dose of placebo
Sponsors
Enze Hospital, Taizhou Enze Medical Center (Group)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with abnormally elevated urinary cysteine concentration or clear hexagonal crystals in urine sediment; 2.The analysis of stone composition is for pure CS patients or mixed CS patients with complete clinical data; 3.There is no age limit for carriers of SLC3A1/SLC7A9 pathogenic mutation genes.
Exclusion criteria
Exclusion criteria: 1.Mixed type CS with incomplete clinical data; 2.Loss to follow-up; 3.In the pharmacological intervention phase, hyperkalemia (serum potassium > 5.0 mmol/L) is further restricted, patients with moderate to severe renal impairment (eGFR < 45 mL/min/1.73 m²) or receiving potassium-sparing diuretics are excluded, and patients receiving angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, or tacrolimus are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene sequencing of embryo lines SLC3A1 and SLC7A9;24-hour urine Cysteine, Lysine, Ornithine, Arginine;Urine pH; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour urinary creatinine;24-hour urine calcium ions, magnesium ions, oxalate ions, phosphate ions, citrate ions; | — |
Countries
China
Contacts
Public ContactHongyuan Yu
Enze Hospital, Taizhou Enze Medical Center (Group)
Outcome results
None listed